Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study
Authors:
Open Access
- 1 April 2015
- journal article
- research article
- Published by Elsevier in The Lancet Global Health
- Vol. 3 (4) , e217-e228
Abstract
No abstract availableKeywords
Funding Information
- Hong Wang (Bill & Melinda Gates Foundation)
- Shenglan Tang (Duke University)
- Christopher Fitzpatrick (WHO)
This publication has 35 references indexed in Scilit:
- Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey dataThe Lancet, 2014
- Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance dataThe Lancet Infectious Diseases, 2013
- Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesEuropean Respiratory Journal, 2012
- Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysisEuropean Respiratory Journal, 2012
- National Survey of Drug-Resistant Tuberculosis in ChinaNew England Journal of Medicine, 2012
- Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority NeedsThe Journal of Infectious Diseases, 2012
- Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional studyThe Lancet, 2012
- Inappropriate Tuberculosis Treatment Regimens in Chinese Tuberculosis HospitalsClinical Infectious Diseases, 2011
- MDR Tuberculosis — Critical Steps for Prevention and ControlNew England Journal of Medicine, 2010
- GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysisEuropean Respiratory Journal, 2008